Respiratory morbidities in late preterm and term infants with myelomeningocele.

Objective: To describe the incidence of respiratory morbidities in late preterm and term newborns with myelomeningocele (MMC) born by c-section.

Study Design: Single center retrospective cohort study of infants born between 34 0/7 and 40 6/7 weeks gestation with the diagnosis of MMC. The primary outcome was the incidence of respiratory morbidities and the secondary outcome was caffeine treatment for apnea at discharge.

Milrinone Pharmacokinetics and Pharmacodynamics in Neonates with Persistent Pulmonary Hypertension of the Newborn.

 To describe the pharmacokinetics and pharmacodynamics of milrinone in infants with persistent pulmonary hypertension of the newborn (PPHN) and to explore the impact of age on milrinone disposition.  Randomized, open label pilot study.  Multicenter; level 3 and level 4 neonatal intensive care units.

Definitions of extubation success in very premature infants: a systematic review.

Objective: Studies of extubation in preterm infants often define extubation success as a lack of reintubation within a specified time window. However, the duration of observation that defines extubation success in preterm infants has not been validated. The purpose of this study was to systematically review published definitions of extubation success in very preterm infants and to analyse the effect of the definition of extubation success on the reported rates of reintubation.

Quality of reporting of neonatal and infant trials in high-impact journals.

Objectives: To perform a systematic review of the quality of reporting for randomized controlled trials (RCTs) with infants and neonates that were published in high-impact journals and to identify RCT characteristics associated with quality of reporting.

Methods: RCTs that enrolled infants younger than 12 months and were published in 2005-2009 in 6 pediatric or general medical journals were reviewed. Eligible RCTs were evaluated for the presence of 11 quality criteria selected from the Consolidated Standards of Reporting Trials guidelines.